Evidence map›Paper›PMID 37501595›Full record

ArticleTumori2023

Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma.

Michele Dionese, Francesco Pierantoni, Elisabetta Bezzon, Enrico Cumerlato, Davide Bimbatti, Umberto Basso, Marco Maruzzo, Vittorina Zagonel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tumori, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Michele DioneseOncology 1 Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.ORCID 0000-0002-3964-2866
Francesco PierantoniDepartment of Surgery, Oncology and Gastroenterology, University of Padua., Padua, Italy.
Elisabetta BezzonRadiology Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
Enrico CumerlatoOncology Unit, Azienda ULSS 6 Euganea, Schiavonia, Italy.
Davide BimbattiOncology 1 Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
Umberto BassoOncology 1 Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
Marco MaruzzoOncology 1 Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
Vittorina ZagonelOncology 1 Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
Istituto Oncologico Veneto · ITAULSS 2 Marca Trevigiana · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvaluation of tumor response according only to dimensional criteria may underestimate treatment benefit in patients treated for metastatic renal cell carcinoma (RCC). In this study we evaluated the role of lesion enhancement modifications and Choi criteria in patients affected by renal cell carcinoma treated with immunotherapy.

methodsWe collected data of 60 consecutive patients (with a total of 154 measurable lesions) treated with immunotherapy (nivolumab or ipilimumab plus nivolumab) at a single Institution. We evaluated tumour response using both RECIST1.1 criteria and Choi criteria at the first radiological assessment; we subsequently associated response with progression free survival and overall survival.

resultsChoi criteria found a higher rate of objective response compared to RECIST criteria (38.3% vs 18.3%). An objective response according to both criteria was associated with longer progression free survival and overall survival. Response rate for Choi did not vary according to lesion site.

conclusionChoi criteria seemed to be able to predict clinical benefit in a higher proportion of patients with renal cell carcinoma treated with immunotherapy than RECIST criteria. Partial response according to RECIST was confirmed as a predictor of longer progression-free survival and overall survival.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansImmunotherapyNivolumabRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeNivolumabChoiimmunotherapyMetastatic renal cell carcinomaRECISTresponse evaluationtumor attenuation

Identifiers

PMID37501595
PMCPMC10702307
OpenAlexW4385331592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.